M&A Readiness in 2026: What Buyers Are Underwriting
Intelligence for B2B healthcare founders navigating exit optionality. Based on off-the-record conversations with 30+ active acquirers, PE dealmakers, and investment bankers.
January 2026
Strategic M&A is the most likely exit path for healthcare founders over the next 3–5 years. That part most people know. What most founders don't see is how much the process itself determines the outcome.
We spent three months talking to the people who run these deals: PE firms, corporate acquirers, investment bankers, all active in healthcare right now. We asked them what they underwrite first, where deals die, and what separates the companies that close from the ones that stall out at diligence.
The short version: buyers aren't passing on companies because the product is wrong. They're passing because the deal is too expensive to close. Messy financials, integration burden, governance that takes a lawyer to explain. In a market where buyers have options, they pick the deals that move cleanest.
This report maps what we learned.
Who's on the other side of your deal, and what they care about
Healthcare M&A has three actors, and they're all optimizing for something different. Most founders engage late enough that they never learn this until it costs them.
PE firms: underwrite cash flow and repeatability. They also price in everything that adds friction: preference stacks, valuation anchoring to a 2021 round, governance that requires five signatories to close. Several PE buyers told us they prefer bootstrapped companies outright, because the waterfall is cheaper and the deal closes faster.
Corporate acquirers: almost never buy cold. They partner first, test the integration, build internal champions, and acquire only after the capability is proven and the risk is understood. One corporate development lead was blunt: if you don't have a relationship with us already, a cold process is a long shot.
Investment bankers: run deals that are ready to close. They're not rescue operations. When a founder shows up at six months runway asking for help, the math is already against them. The bankers we talked to said the same thing in different words: call us 12–36 months before you want to transact. By the time you need us, you've already lost most of your leverage.
Understanding how each group makes decisions is the difference between running a credible process and spending six months learning it the hard way.
Five forces shaping which healthcare deals close in 2026
The full report maps five structural forces driving deal activity. Two worth previewing here:
Buyers now require proof before they'll engage on price.The metric stack is consistent across PE and strategic acquirers: year-over-year growth, gross margin, burn rate, net revenue retention, revenue per employee. A founder who can't walk through unit economics in a five-minute conversation doesn't get a second meeting. Growth without economics isn't a strategy anymore. It's a red flag.
There's also a dead zone in venture-backed healthcare that nobody talks about. Companies between $5M and $20M in revenue, past the early stage, generating real revenue, but not big enough for bankers to prioritize and not returning a fund for their VCs. These are viable businesses sitting in an incentives gap. Nobody is economically motivated to help them find the right path, even though the right exit could return meaningful capital.
The report covers three additional forces, including why diligence readiness has become a competitive advantage, how timing kills more deals than product quality, and what the corporate partner-to-acquisition model means for exit planning.
Seven diligence gates that determine whether your deal moves forward
Before price becomes a conversation, buyers run a set of tests. We synthesized what we heard into seven diligence gates: the areas where healthcare deals advance, stall, or die.
None of these are solved during diligence. They're built in the quarters before, through operating proof. A Quality of Earnings review that should take three weeks stretches past two months when the books aren't clean. That delay alone can kill a deal.
The full report breaks down how buyers test each gate, the failure patterns we heard repeatedly, and what to have ready before a process starts.
Your leverage decays on a schedule
Runway is a negotiating position. Below 12 months, the conversation shifts from what you're worth to what terms a buyer requires to take the risk.
| Runway | Buyer perception | Founder leverage | Banker engagement |
|---|---|---|---|
| 18+ months | Optionality | High | Ideal timing |
| 12–18 months | Credible positioning window | Medium-high | Engageable |
| 6–12 months | Compressed process | Low | Selective |
| Below 6 months | Distressed | Minimal | Rarely |
The full report includes the complete leverage decay table, timing strategy for each stage, and specific moves whether you're 18 months out or running low on runway right now.
This report covers healthcare M&A exits in the $10–100M enterprise value range. Primarily B2B. Every deal is different, and what follows are patterns from real conversations, not guarantees. If you're a founder weighing exit timing, a PE investor evaluating a portfolio company, or a banker scoping a new healthcare mandate, this was written with you in mind.
Access the Full Report
What buyers test first, where founders lose leverage, and what to do about it.